menu

MENU

繁體中文

Contact Us

Menu

Menu

Company

Introduction
Team & Board of Directors
Partners
Investors
Latest News

R&D Pipeline

Overview
Intranasal Vaccines
Asthma Immunotherapy
Respiratory Antiviral Immunotherapy

Company

Introduction

Team & Board of Director

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Contact us

March 26, 2022

Safety Review Team Meeting Held for Cohort 2 (Mid-Dose Group) of New Drug AD17002-AI Trial; Expert Committee Approves Enrollment for Next Phase High-Dose Group.

‍

Social Share

Related Content

September 25, 2026

Advagene's New Drug Demonstrates Potential Against SARS-CoV-2: 《Journal of Microbiology, Immunology and Infection》Publication Highlights Mucosal Immunity and Lung Protection

August 4, 2026

The Phase II clinical trial of new drug, AD17002, for the treatment of moderate-to-severe asthma has completed the enrollment of all 127 subjects.

December 18, 2025

The Company Announces First Subject Enrolled in Phase II Clinical Trial of Investigational New Drug AD17002 for Moderate-to-Severe Eosinophilic Asthma.